

## GUIDELINES

# Pemphigus. S2 Guideline for diagnosis and treatment – guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)

M. Hertl,<sup>1,\*</sup> H. Jedlickova,<sup>2</sup> S. Karpati,<sup>3</sup> B. Marinovic,<sup>4</sup> S. Uzun,<sup>5</sup> S. Yayli,<sup>6</sup> D. Mimouni,<sup>7</sup> L. Borradori,<sup>8</sup> C. Feliciani,<sup>9</sup> D. Ioannides,<sup>10</sup> P. Joly,<sup>11</sup> C. Kowalewski,<sup>12</sup> G. Zambruno,<sup>13</sup> D. Zillikens,<sup>14</sup> M.F. Jonkman<sup>15</sup>

<sup>1</sup>Department of Dermatology, Philipps-University Marburg, Marburg, Germany

<sup>2</sup>Department of Dermatology, Masaryk University, Brno, Czech Republic

<sup>3</sup>Department of Dermatology, Semmelweis University Budapest, Budapest, Hungary

<sup>4</sup>Department of Dermatology, School of Medicine University of Zagreb, Zagreb, Croatia

<sup>5</sup>Department of Dermatology, Akdeniz University, Antalya, Turkey

<sup>6</sup>Department of Dermatology, Karadeniz Technical University, Trabzon, Turkey

<sup>7</sup>Department of Dermatology, Tel-Aviv University, Tel-Aviv, Israel

<sup>8</sup>Department of Dermatology, University of Bern, Inselspital, Switzerland

<sup>9</sup>Department of Dermatology, University of Parma, Parma, Italy

<sup>10</sup>Department of Dermatology, Aristotle University of Thessaloniki, Thessaloniki, Greece

<sup>11</sup>Department of Dermatology, Rouen University Hospital, Rouen, France

<sup>12</sup>Department of Dermatology, Medical University of Warsaw, Warsaw, Poland

<sup>13</sup>Department of Dermatology, L'Istituto Dermopatico dell'Immacolata, Rome, Italy

<sup>14</sup>Department of Dermatology, University of Lübeck, Lübeck, Germany

<sup>15</sup>Department of Dermatology, University of Groningen, Groningen, The Netherlands

\*Correspondence: M. Hertl. E-mail: hertl@med.uni-marburg.de

## Abstract

**Background** Pemphigus encompasses a group of life-threatening autoimmune bullous diseases characterized by blisters and erosions of the mucous membranes and skin. Before the era of immunosuppressive treatment, the prognosis of pemphigus was almost fatal. Due to its rarity, only few prospective controlled therapeutic trials are available.

**Objectives** For this reason, a group of European dermatologists with a long-standing interest and expertise in basic and clinical pemphigus research has sought to define diagnostic and therapeutic guidelines for the management of patients with pemphigus.

**Results** This group identified the statements of major agreement or disagreement regarding the diagnostic and therapeutic management of pemphigus. The revised final version of the pemphigus guideline was finally passed on to the European Dermatology Forum (EDF) for a final consensus with the European Academy of Dermatology and Venereology (EADV) and the European Union of Medical Specialists (UEMS).

Received: 3 March 2014; Accepted: 10 September 2014

## Conflicts of interest

M. Hertl is member of the Advisory Boards of Roche, Biogen Idec, Ammiral and UCB, is speaker for Biotest, medac and MSD, and member of the Westat DSMB. He also received grants from Biogen Idec and Fresenius.

D. Zillikens acts as a consultant for Euroimmun and Ammiral, received payments for lectures including service on speakers bureaus from Euroimmun, Fresenius, Miltenyi and Roche as well as grants from Euroimmun, Miltenyi, Fresenius, Biotest, Dompé and Ammiral.

All other authors declare that they have no financial or other relationships that might lead to a conflict of interest.

## Funding sources

The development of the guideline was partly supported by the European Dermatology Forum (EDF).

## Introduction

Pemphigus encompasses a group of life-threatening autoimmune bullous diseases characterized by flaccid blisters and erosions of the mucous membranes and skin.<sup>1–3</sup> The severity of the disease is based on its progressive course which is accompanied by an increased body catabolism with loss of body fluids and proteins and secondary bacterial and viral infections which may lead to sepsis and cardiac failure. Before the advent of systemic corticosteroids, the prognosis of pemphigus was almost fatal within 2 years after making the diagnosis. Pathophysiologically, the underlying intraepithelial blister formation is caused by IgG autoantibodies against the desmosomal adhesion proteins, desmoglein 3 and/or desmoglein 1, on epidermal keratinocytes.<sup>4</sup> Pemphigus is rare and its incidence has been estimated to about two new patients per 1 million inhabitants per year in Central Europe. Two main clinical variants are known, pemphigus vulgaris (PV) and pemphigus foliaceus (PF). The pathogenic role of anti-desmoglein 1/3 IgG has been clearly established since the injection of patients' sera or affinity-purified IgG from pemphigus sera into neonatal mice reproduces immune pathologically and clinically the cardinal symptoms of pemphigus within 24 h.<sup>5</sup> In most patients, disease activity is closely correlated with serum levels of desmoglein-reactive autoantibodies. Due to its rarity, only few prospective controlled clinical trials are available in pemphigus, which are limited by the low numbers of patients studied and the lack of statistically significant differences in many studies. A few studies compared different doses of prednisolone, i.v. corticosteroid pulses versus placebo, azathioprine versus mycophenolate mofetil and the use of adjuvant treatment with methotrexate, cyclosporine, cyclophosphamide and high-dose intravenous immunoglobulins (IVIg).<sup>6,7</sup> The combination of systemic corticosteroids (prednisolone, 1.0–1.5 mg/kg/day) and corticosteroid-sparing immunosuppressive drugs, mostly azathioprine and mycophenolate mofetil, is regarded as standard first-line therapy by most dermatologists.

However, no internationally accepted treatment guidelines exist<sup>8</sup> despite efforts to provide national guidelines in several European countries such as in France<sup>9</sup> and United Kingdom.<sup>10</sup> For this reason, a group of European dermatologists with a long-standing interest and expertise in basic and clinical pemphigus research has sought to define diagnostic and therapeutic guidelines for the management of patients with pemphigus.

## Methodology of guideline preparation

To facilitate this process in the present pemphigus guideline, a working group of European dermatologists followed a strategy which had been previously used by a group of French dermatologists (French guidelines). In a first step, a group of experts

(working group) wrote the first version of the guidelines which was based on a recently established French guideline for the management of pemphigus.<sup>9</sup> Thereafter, a second group of experts (notation group) gave marks (ranging from 0 to 9 according to the increasing degree of consensus) to each of the statements of the first version of the guidelines. This process identified the statements of major agreement or disagreement. Based on the marks of the notation group, the working group then prepared a second version of the guideline which led to a consensus in all the remaining critical statements. The revised version of the pemphigus guideline was finally passed to the European Dermatology Forum (EDF) for a final consensus of the EDF members.

## Initial evaluation of pemphigus

The initial clinical examination should seek basic evidence for the diagnosis of pemphigus, as well as screening for comorbidities.

## Major objectives

- To confirm the clinical diagnosis of pemphigus
- To search for risk factors, severity factors and potential comorbidities based on history and initial clinical evaluation
- To specify the type of initial involvement (skin, mucosa) and its extent
- To evaluate the prognosis depending on the age of the patient and general condition (Karnovsky score, optional)
- To measure extent and distribution of the lesions by Auto-immune Bullous Skin Intensity and Severity Score (ABSIS) or Pemphigus Disease and Area Index (PDAI) (both optional)
- To start treatment

## Professions involved

The treatment plan for patients with pemphigus is the responsibility of an experienced dermatologist, usually a hospital-based dermatologist in a tertiary referral centre, a specialized centre or a member of a network.

Other health professionals who may have supportive functions are as follows:

- The consultant dermatologist in general practice
- The patient's general practitioner
- All other specialists whose expertise is necessary, based on general clinical condition, comorbidities, such as internists, cardiologists, stomatologists, ophthalmologists, otorhinolaryngologists, gastroenterologists, gynaecologists, urologists, proctologists, rheumatologists, oncologists and psychologists
- Health nurses in selected cases in which home care is required and applicable, e.g. elderly or disabled patients with residual mucosal or skin lesions following hospitalization

- Dietician, physiotherapist
- Nurse specialist/practitioner

### Clinical examination

#### Medical history

- It should specify the time of first onset of symptoms
- It should specify functional symptoms, i.e. pain, pruritus, intensity of dysphagia, ocular and ENT symptoms, dysuria, anogenital problems and weight loss
- It should include a haematological, oncologic, endocrine, cardiovascular and infectious medical history to search for risk factors of oral corticosteroid treatment and evolving complications of immunosuppressive therapy
- It should evaluate anticipated pregnancy, actively practiced contraception (especially if immunosuppressive treatment is being considered)
- It should search for recent drug intake which may potentially induce pemphigus, such as D-penicillamine, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta blockers, cephalosporins, phenylbutazone, pyritinol, and thiopronine
- It should assess the psychological tolerance of potential side-effects due to treatment, especially corticosteroids
- It should seek to evaluate the disease impact on quality of life

#### Physical examination

##### General

- It should assess the extent of skin lesions and all mucous membranes, the degree of mucosal damage and functional impairment (dysphagia, dysphonia, weight loss, impairment of vision and dyspareunia)
- It should also assess the patient's general condition and comorbidities:
  - Bodyweight,
  - Arterial blood pressure,
  - General condition (Karnovsky index), comorbidities (neoplastic, cardiovascular, musculoskeletal, diabetes, etc.),
- Direct Nikolsky's sign (type I) in normal-appearing skin for monitoring of disease activity: ability to split the epidermis on skin areas distant from the lesions by a lateral pressure with a finger,
- Marginal Nikolsky's sign (type II) in perilesional skin for diagnosis: ability to split the epidermis of the skin far beyond the pre-existing erosion, extending to a great distance on the normal-appearing skin, by pulling the remnant of a ruptured blister or rubbing at the periphery of existing lesions

#### *Pemphigus vulgaris* (PV)

- Usually begins with oral mucosal lesions: buccal and/or gingival painful, persisting erosions which interfere with eating.

Less common are non-cicatricial ocular lesions, nasal, laryngeal, oesophageal and rectal erosions are also possible

- Cutaneous involvement (which may appear several weeks or months after the first appearance of mucosal lesions) presents flaccid bullae with clear content, present on non-erythematous skin quickly transforming into post-bullous erosions
- The lesions may be localized or generalized and predominate at seborrhoeic areas (chest, face, scalp, interscapular region) and mechanically stressed regions as well as on the extremities
- The disease is usually not associated with major pruritus
- Fingernail involvement is possible

#### *Pemphigus vegetans*

*Pemphigus vegetans* is a rare but distinct clinical form of PV characterized by verruciform and papillomatous vegetating and/or pustular lesions of the periorificial regions or, more commonly, involving the large folds.

It may present in two forms:

- Neumann-type pemphigus vegetans is characterized by periorificial papillomas
- Hallopeau-type pemphigus vegetans by pustular lesions, predominantly involving the large folds

#### *Pemphigus foliaceus* (PF)

Including rare pemphigus erythematous:

- Cutaneous involvement: transient, flaccid bullae or puff pastry-like exfoliation transforming into crusty erosions in seborrhoeic skin areas (chest, scalp, face, interscapular region)
- More extensive cutaneous involvement in sporadic and endemic pemphigus foliaceus ('Fogo Selvagem', Brazilian pemphigus, Tunisian pemphigus)
- No mucosal involvement

#### *Paraneoplastic pemphigus* (PNP)/*paraneoplastic autoimmune syndrome* (PAMS)

To be suspected in the context of concomitant malignancy, particularly non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, thymoma or Castleman's disease. In up to one third of cases, the underlying malignancy has not been diagnosed at the time of diagnosis.

Moreover, the symptoms of PNP/PAMS can precede the malignancy:

- Mucosal involvement: initially limited cheilitis and/or ulcerative stomatitis, persisting painful erosions which lead to severe dysphagia. Cicatricial conjunctivitis, keratitis and genital involvement are common. Possible pharyngeal involvement, as well as involvement of the nasal cavity and oesophagus can lead to phagodynia and gastro-oesophageal reflux.
- Cutaneous polymorphic involvement with symptoms resembling mild lichen planus-like to graft-versus-host

disease-like, erythema multiforme-like, bullous pemphigoid-like or pemphigus vulgaris-like eruption. Palmar involvement is common

- Pulmonary involvement (alveolitis, bronchiolitis obliterans, pulmonary fibrosis) is a characteristic and life-threatening complication

#### *IgA pemphigus*

- Two clinical variants: subcorneal pustular dermatosis type with pustules on erythematous plaques on extremities and intraepidermal neutrophilic type (IEN) with pustules in sunflower arrangement on the trunk

#### Laboratory investigations (summarized in Table 1)

Confirm the clinical diagnosis of pemphigus. The diagnosis of pemphigus is based on four criteria:

- Clinical presentation (see Clinical Examination)
- Histopathology
- Direct immunofluorescence microscopy (DIF) of perilesional skin
- Serological detection of serum autoantibodies against epithelial cell surface by indirect immunofluorescence microscopy (IIF) and/or enzyme-linked immunosorbent assay (ELISA)

#### Histopathology

Preferentially, a 4-mm-punch excision should be taken of a fresh (<24 h) small vesicle or 1/3 of the peripheral portion of a blister and 2/3 perilesional skin (placed in 4% formalin solution) for routine histopathological analysis: intraepidermal suprabasal acantholysis in PV and PNP, or acantholysis at the granular layer in PF. Epidermal acantholysis, suprabasal cleft formation, dyskeratotic keratinocytes, vacuolar change of the basilar epidermis and epidermal exocytosis of inflammatory cells (PNP).

#### Direct immunofluorescence microscopy (DIF)

Skin biopsy of perilesional skin (up to 1 cm from a fresh lesion), put into a cryotube for transportation in a cylinder of liquid nitrogen or in saline (delivery <36 h) or Michel's fixative for DIF analysis:

- DIF: IgG and/or C3 deposits at the surface of epidermal keratinocytes
- The epithelial cell surface staining for *in vivo* IgG depositions is normally granular in DIF and smooth in IIF
- IgA deposits with an epithelial cell surface pattern in addition to IgG may be present in a minority of cases. When only IgA is found, the diagnosis of IgA pemphigus is established

**Table 1** Pemphigus: diagnostic algorithm

<b>Histopathology</b> (1) Suprabasal loss of epidermal adhesion (PV, PNP, IgA-IEN) (2) Subcorneal loss of epidermal adhesion (PF, IGA-SPD)	<b>Additional considerations</b> (Ad 1 and 2) The biopsy should include preferentially a fresh entire blister or at least part of a blister with perilesional skin. Characteristic is an eosinophilic epidermal infiltrate (PV), neutrophilic epidermal infiltrate (PF, IgA-SPD, IgA-IEN) or interface dermatitis (PNP)
<b>Direct immunofluorescence microscopy</b> (1) Anti-epithelial cell surface IgG deposits in the epidermis (PV, PF) (2) Anti-epithelial cell surface IgA deposits in the epidermis (IgA-SPD, IgA-IEN) (3) Anti-epithelial cell surface IgG deposits and C3 and/or IgG deposits at the dermal-epidermal junction (PNP)	<b>Additional considerations</b> (Ad 1–3) The biopsy should be taken from perilesional skin
<b>Indirect Immunofluorescence microscopy</b> (1) Anti-epithelial cell surface IgG deposits on the epithelium of monkey oesophagus (PV, PF, PNP) (2) Anti-epithelial cell surface IgA deposits on the epithelium of monkey oesophagus (IgA-SPD, IgA-IEN) (3) Anti-epithelial cell surface IgG reactivity with the epithelium of rat/monkey bladder (PNP)	<b>Additional considerations</b> (Ad 1) Majority of PV, PF and PNP sera are positive on monkey oesophagus. (Ad 2) Only ca. 50% of the IgA pemphigus sera show reactivity with monkey oesophagus (Ad 3) Standard substrate to detect IgG reactivity against plakins
<b>Enzyme-linked immunosorbent assay (ELISA)</b> (1) Desmoglein 3-ELISA (PV, PNP) (2) Desmoglein 1-ELISA (PF, PV, PNP) (3) Periplakin/Envoplakin-ELISA (PNP) (4) Desmocollin 3-ELISA (PNP, IgA-IEN) (5) BP230-ELISA (PNP)	<b>Additional considerations</b> (Ad 1) Dsg3-ELISA positive in mucosal PV and PNP. In general, IgG titres relate to disease activity (Ad 2) Dsg1-ELISA positive in cutaneous PV and frequently in PNP. In general, IgG titres relate to disease activity (Ad 3) Additional serological parameter for PNP; sensitivity of the ELISA at 85–90% (Ad 4) Dsc3-ELISA frequently positive in atypical pemphigus, i.e. clinical cases reminiscent of PV or PF which lack IgG reactivity against Dsg3 and/or Dsg1 (Ad 5) BP230-ELISA frequently positive in PNP but of minor diagnostic importance

IgA-IEN, intraepidermal neutrophilic type of IgA pemphigus; IgA-SPD, subcorneal pustular dermatosis type of IgA pemphigus; PF, pemphigus foliaceus; PNP, paraneoplastic pemphigus; PV, pemphigus vulgaris.

- Epithelial cell surface deposits can sometimes be associated with linear deposits of IgG or C3 along the dermal–epidermal junction, suggestive of PNP/PAMS or pemphigus erythematosus, or the coexistence of pemphigus and pemphigoid
- In specialized laboratories, plugged hairs can be utilized for DIF for the diagnosis of pemphigus

#### *Immune serological tests*

In addition to DIF, IIF and additional techniques with defined native or recombinant proteins are commonly used to detect serum autoantibodies in patients with pemphigus.

#### *Indirect immunofluorescence microscopy (IIF)*

- IIF test on monkey oesophagus or human skin to search for autoantibodies against surface proteins of epidermal keratinocytes. The smooth and reticular staining pattern is also referred to as ‘chicken wire’, ‘honeycomb’ or ‘fish-net-like’
- In case of atypical presentation or the suspicion of an unrelated autoimmune bullous disorder, additional immunopathological tests may be performed, such as IIF on rat bladder and immunoblot/immunoprecipitation
- IIF on rat bladder (in suspected cases of PNP/PAMS with extracts of epidermal keratinocytes) is highly specific but less sensitive

#### *ELISA*

- Detection of anti-desmoglein 1 (Dsg1) (PF/mucocutaneous PV) and/or anti-desmoglein 3 (Dsg3) IgG autoantibodies (mucosal PV) by ELISA (MBL, Euroimmun)
- The detection of IgG autoantibodies by ELISA is positive in more than 90% of cases
- In general, the ELISA index correlates with the extent and/or activity of disease (see remark above and prognostic value for relapse, helping to guide treatment). Large prospective cohort studies are, however, missing in this context to provide reliable data about predictive value

#### *Immunoblot and immunoprecipitation*

Diagnosis of PNP/PAMS: immunoblot and immunoprecipitation with keratinocyte extracts will reveal evidence of serum IgG/IgA autoantibodies against:

- Envoplakin (210 kDa) and periplakin (190 kDa) (Euroimmun)
- Desmoglein 3 (130 kDa), desmoglein 1 (160 kDa), desmocollins, desmoplakins I and II, BP180/BPAG2, BP230/BPAG1, plectin (500 kDa) and alpha-2-macroglobulin-like-1 (A2ML-1, 170 kDa)

- IgG antibodies against envoplakin and periplakin and/or A2ML1 confirm the clinical diagnosis of PNP/PAMS. IgG against desmoplakins I and II, BP230/BPAG1 and plectin may be present in other forms of pemphigus
- Combining two of three serological techniques (IIF on rat bladder, immunoblot and immunoprecipitation) is sufficient for making the diagnosis of PNP/PAMS (sensitivity almost 100%)<sup>11</sup>

#### *Work-up before corticosteroid or immunosuppressive therapy*

- Complete blood count
- Creatinine, blood electrolytes
- Transaminases, gamma GT, alkaline phosphatase
- Total serum protein, albumin
- Fasting serum glucose
- Hepatitis B, C and HIV
- Chest X-ray

Recommended, on indication or optional:

- Serum IgA deficiency should be ruled out prior to IVIG treatment
- Analysis of thiopurine methyltransferase (TPMT) activity is recommended when azathioprine is considered<sup>12</sup>
- Abdominal sonography is optional
- Quantiferone or PPD is recommended in case of elevated risk for TB
- G6PD serum activity, bilirubine, reticulocytes if dapsone is considered
- $\beta$  HCG to exclude pregnancy in females of childbearing age
- Osteodensitometry is recommended prior to glucocorticoid treatment
- Ocular examination (glaucoma, cataract) is recommended

## **Therapeutic management**

### **Objectives**

Control and healing of the bullous skin and/or mucous lesions is the primary objective as well as attempting to minimize, as much as possible, serious side-effects of treatment. The treatment aims are as follows:

- Healing of the bullous eruption and disappearance of the functional impairment associated with the disease
- Prevent/strictly limit the appearance of recurrences
- Improve the quality of life of the patients
- Limit common side-effects usually associated with long-term immunosuppressive or corticosteroid treatment

### **Professionals involved**

- The initial management, diagnosis and treatment of extensive manifestations of the disease usually require hospitalization in a dermatology department

- This is continued until clinical control of the bullous eruption is achieved
- In limited forms of pemphigus, additional diagnostic examinations and clinical monitoring can be either performed in an inpatient or outpatient setting
- Overall management is coordinated by the dermatologist in liaison with the referring dermatologist, the general physician and other medical specialists and hospital doctors from the centre of reference and/or geographical area (if a reference centre exists in the particular country).
- Specialists and health professionals involved are identical to those listed in the initial evaluation (see Professions involved)
- Exceptionally, the disease can occur during childhood, and children should be supported by a multidisciplinary team, jointly by a reference centre, a paediatric dermatology department or a paediatrician
- Systemic corticosteroids can be combined with an immunosuppressive adjuvant at the start of therapy, particularly in cases of increased risk of corticosteroid therapy, complications due to expected prolonged use (>4 months) or dose dependency above minimal therapy (>10 mg/day). However, there is only fair evidence that addition of adjuvants is superior to treatment with glucocorticoids alone
- Oral corticosteroid pulses do not appear to have additional benefit on top of conventional first-line treatment with oral predniso(lo)ne and immunosuppressive adjuvants.<sup>13,14</sup> Still, more evidence is needed and steroid pulse therapy should be reserved for refractory pemphigus patients

#### *Immunosuppressive adjuvants*

Based on the current evidence, adjuvants have only a steroid-sparing effect and may lead to steroid-free remission.<sup>7,15–19</sup>

#### *First-line adjuvants*

- Azathioprine (1–3 mg/kg/day). Start first week 50 mg/day to detect idiosyncratic reactions (and in case stop immediately), and then raise to desired dose. Even though not predictive for idiosyncratic reactions, thiopurine methyltransferase activity should be monitored prior to treatment because the recommendations for azathioprine dosing vary based upon TPMT activity.<sup>20,21</sup> In general, adults with pemphigus and high TPMT activity are treated with normal doses of azathioprine (up to 2.5 mg/kg/day), patients with

### **Therapeutic management (summarized in Table 2)**

#### *First-line treatment*

- Systemic corticosteroid therapy (predniso(lo)ne at 0.5 mg to 1.5 mg/kg/day)
- Control of PF generally requires lower doses than PV
- If initial control of PV is not reached within 2 weeks, a higher predniso(lo)ne dose (up to 2 mg/kg) is optional

**Table 2** Pemphigus: therapeutic algorithm

First-line treatment	Comments
(1) Predniso(lo)ne	(Ad 1) Initially 0.5 mg to 1.5 mg/kg/day. Optimal dose not validated. Taper by 25% reduction in biweekly steps, at <20 mg/d more slowly. Add proton pump inhibitors/H2 blockers, vitamin D and calcium
Second-line treatment (in refractory disease or in case of contraindications to glucocorticoids)*	Comments
(1) Azathioprine or (2a) Mycophenolate mofetil or (2b) Mycophenolic acid	(Ad 1) 1–3 mg/kg/day. Check TPMT activity prior to treatment. Start with 50 mg/day. Steroid-sparing effect demonstrated (Ad 2a) 2 g/day. Steroid-sparing effect demonstrated. Raise daily dose by 1 capsule/ week to increase GI tolerance (Ad 2b) 1440 mg/day. Steroid-sparing effect demonstrated. Raise daily dose by 1 capsule/ week to increase GI tolerance
Third-line treatment (in refractory disease or in case of contraindications to immunosuppressants)	Comments
(1) Anti-CD20 monoclonal antibody (rituximab)	(Ad 1) 2 × 1 g i.v. (2 weeks apart) or 4 × 375 mg/m <sup>2</sup> (each 1 week apart). Exclude hypersensitivity to mouse proteins. PML is a rare but potentially fatal complication
(2) Intravenous immunoglobulins	(Ad 2) (2 g/kg/month). Exclude IgA deficiency before treatment. Has been used in combination with rituximab and cyclophosphamide
(3) Immunoabsorption	(Ad 3) 2 cycles à 4 days (2.5-fold total plasma volume/d), 4 weeks apart. Has been used in combination with rituximab and cyclophosphamide
(4) Cyclophosphamide	(Ad 4) 500 mg as i.v. bolus or given orally at 2 mg/kg/day. Steroid-sparing effect demonstrated. Consider secondary sterility, haemorrhagic cystitis and secondary cancer
(5) Dapsone	(Ad 5) 100 mg/day or up to ≤1.5 mg/kg/day. Check serum G6PD activity before treatment. Steroid-sparing effect demonstrated
(6) Methotrexate	(Ad 6) 10–20 mg/week. Substitute folate 5–15 mg on the following day

\*Immunosuppressants are commonly used in combination with glucocorticoids. Based on the current evidence, they have a glucocorticoid-sparing effect and may lead to glucocorticoid-free remission.

intermediate or low TPMT activity should receive a lower maintenance dose (up to 0.5 to 1.5 mg/kg/day) depending on level of enzyme activity and patients with lack of TPMT activity should not be treated with azathioprine.

- Mycophenolate mofetil (2 g/day) or mycophenolic acid (1440 mg/day). In case of MMF, consider to raise daily dose by 1 capsule (500 mg) per week until the final dose of 2 g/day for better gastrointestinal tolerance

#### Second-line adjuvants

- Anti-CD20 monoclonal antibody, such as rituximab 2 × 1 g i.v. (2 weeks apart) or 4 × 375 mg/m<sup>2</sup> (each 1 week apart)<sup>22–25</sup>
- IVIG (2 g/kg/month)<sup>26</sup>
- Immunoabsorption (two cycles à four consecutive days are performed 4 weeks apart)<sup>22,27,28</sup>
- Cyclophosphamide (500 mg as i.v. bolus or given orally at 2 mg/kg/day)<sup>29,30</sup>
- Methotrexate (10–20 mg/week)<sup>31</sup>
- Dapsone 100 mg/day or up to ≤1.5 mg/kg/day<sup>32</sup>

#### Additional supportive treatment

- Intralesional injections of corticosteroids (triamcinolone acetonide) may be beneficial for isolated lesions of oral mucosa, lips and skin
- Topical treatment with potent corticosteroids (clobetasol propionate) or calcineurin inhibitors applied directly to the lesions, and oral typical corticosteroids (such as triamcinolone acetonide gel) directly to oropharyngeal erosions for use in combination with systemic therapy, may be beneficial<sup>33,34</sup>
- The use of baths containing antiseptics such as chlorhexidine is recommended
- If there are erosive lesions, they may be covered using different low adhesive wound dressings or local emollients, and compresses
- Analgesics (paracetamol, metamizol and opioids) may be necessary
- Gels containing local anaesthetics may be used for application at the mucosal surfaces
- Proper dental care is required
- Nutritional management with the help of a dietician or a nutritionist if malnutrition is related to oral involvement or systemic corticosteroid therapy

#### Measures in prolonged corticosteroid therapy

- Osteoporosis baseline screening and prophylaxis
- Treat with the smallest dose of glucocorticoid for the shortest time possible to minimize risk of osteoporosis
- Vitamin D and calcium supplementation is recommended at initiation of glucocorticoid treatment
- Treatment with bisphosphonates (i.e. alendronate, risedronate) is recommended in patients at risk (post-menopausal

women, men >50 years on glucocorticoid treatment > 3 months) to prevent osteoporosis<sup>35</sup>

- Ophthalmologic evaluation
- Oral topical antifungals recommended for prophylaxis of oro-intestinal conditions
- Systemic antifungals, antiviral and antibiotic treatment should be used when clinically indicated
- Recommendations vary as to whether H2-blockers or proton pump inhibitors are mandatory to prevent gastric/duodenal ulcers. Based on insufficient evidence, the decision should be individualized to the patient, for example, in case of additional treatment with non-steroidal anti-inflammatory drugs<sup>36</sup>
- Anti-thrombotic prophylaxis in case of high risk of thrombosis
- Psychological support if required
- Physiotherapy is often necessary if prolonged corticosteroid therapy is required

#### Vaccinations

Adjuvant immunosuppressants and rituximab contraindicate the use of live vaccines.

It is recommended that patients receiving oral corticosteroids or immunosuppressive therapy may be vaccinated against seasonal influenza, H1N1, tetanus and pneumococci. The level of protection is questionable during systemic immunosuppression.

#### Monitoring

Pemphigus often shows a chronic (relapsing) course which requires close monitoring of clinical symptoms and of potential side-effects inherent to chronic immunosuppressive treatment. Thus, a multidisciplinary approach is commonly required.

#### Objectives

- To evaluate the efficacy and safety of treatment
- To plan the gradual reduction of immunosuppressive treatment, and the duration of maintenance therapy or its discontinuation

#### Definitions for disease outcome parameters<sup>37</sup>

- *Control of disease activity*: The time at which new lesions cease to form and established lesions begin to heal
- *End of consolidation phase*: The time at which no new lesions have developed for a minimum of 2 weeks, approximately 80% of lesions have healed, and when most clinicians start to taper steroids
- *Complete remission on therapy*: A complete remission on therapy is defined as the absence of new or established lesions while the patient is receiving minimal therapy
- *Complete remission off therapy*: A complete remission off therapy is defined as the absence of new and/or established

lesions while the patient is off all systemic therapy for at least 2 months

- *Relapse/flare*: Appearance of  $\geq 3$  new lesions/month that do not heal spontaneously within 1 week, or by the extension of established lesions, in a patient who has achieved disease control
- *Minimal therapy*: Prednisolone (or the equivalent) at  $\leq 10$  mg/day and/or minimal adjuvant therapy for at least 2 months

#### *Approach to be maintained after consolidation phase*

- The evolution is usually slowly favourable, often requiring a period of 1–3 months for complete healing of lesions
- Progressive reduction of oral corticosteroid treatment: start taper steroids as early as disease control is reached, or up to the end of consolidation phase
- Taper predniso(lo)ne by 25% reduction in biweekly steps (at  $< 20$  mg more slowly!)
- If reappearance of  $< 3$  lesions during tapering of oral corticosteroid therapy occurs, go back to last dose
- At relapse, reincrease oral corticosteroid therapy, and go two steps back in previous dose until control of the lesions is achieved within 2 weeks, then resume gradual decrease of systemic corticosteroids. If disease control is not reached go back to initial dose
- If oral corticosteroids are given alone: add an immunosuppressant (especially in case of early-stage relapse occurring despite continued high-dose corticosteroid treatment)
- If oral corticosteroids are already combined with an immunosuppressant: discuss a change in first-line immunosuppressant or the use of a second-line immunosuppressant including immunoadsorption, IVIG or rituximab
- The extent of immunosuppressive therapy increases the risk of side-effects
- The persistence of high levels of anti-Dsg1 by ELISA has a positive predictive value for skin relapses, whereas the persistence of anti-Dsg3 IgG does not necessarily indicate a mucosal relapse

#### *Immunoadsorption*

Immunoadsorption is an option in patients who have not sufficiently responded to first-line treatment, i.e. glucocorticoids in combination with azathioprine or mycophenolate. Immunoadsorption is considered most effective in combination with systemic immunosuppressive drugs.<sup>22,27,28</sup>

- Generally, four treatments of immunoadsorption are performed on four consecutive days (2.5-fold plasma volume/day)
- Treatment is repeated in 4-week intervals
- Immunoadsorption reduces serum IgG concentration against Dsg1 and Dsg3 by 80%

- Contraindications include severe systemic infections, severe cardiovascular diseases, hypersensitivity against components of the immunoadsorption column, treatment with angiotensin-converting enzyme inhibitors and extensive haemorrhagic diathesis

#### *Anti-CD20 monoclonal antibody (Rituximab)*

Rituximab is indicated in patients who remain dependent on more than 10 mg predniso(lo)ne combined with an immunosuppressive adjuvant.<sup>22–25</sup>

- A course of intravenous rituximab  $2 \times 1000$  mg (2 weeks apart or  $4 \times 375$  mg/1 week apart). The need for immunosuppressive adjuvants in rituximab therapy remains unclear
- Treatment can be repeated with rituximab  $2 \times 1000$  mg (2 weeks apart or  $4 \times 375$  mg/1 week apart) in case of clinical relapse or as early as 6 months after treatment.<sup>38</sup> Lower doses of rituximab are less effective<sup>39,40</sup>
- Rituximab can be combined with short-term ( $< 4$  months old) systemic corticosteroids and long-term ( $> 12$  months old) immunosuppressive treatment
- The incidence of unforeseen fatal infections such as progressive multifocal leukoencephalopathy (PML) cannot be estimated due to the rarity of pemphigus

#### *Management of IVIG treatment*

A course of IVIG treatment (2 g/kg/cycle) is applied i.v. over two to five consecutive days (monthly).<sup>26</sup>

- Treatment is generally combined with systemic corticosteroids (initially) and immunosuppressive adjuvants
- Treatment should be performed over several days to avoid headache and nausea
- Aseptic meningitis is a rare but important side-effect of IVIG treatment which needs to be kept in mind in patients who commonly experience episodes of migraine
- Even though rare, complete IgA deficiency is a contraindication for IVIG treatment<sup>41</sup>

#### **Scheduling and content of consultations**

Evaluation of the efficacy of treatment is primarily based on clinical symptoms. The frequency of disease management (physical exam, additional exams) must be adapted:

- to the patient's clinical condition
- to the severity and disease course during treatment
- to the therapeutics used (monitoring, tolerance, side-effects)
- There are two clinical scores, ABSIS and PDAI, which are currently being tried on a research basis for their usefulness as clinical outcome parameters for the evaluation of the extent and activity of pemphigus
- Initially, follow-up visits should be offered on a two-weekly basis until clinical disease control is achieved

- Then, for the next 3 months, monthly clinical follow-ups are recommended, and in the consolidation phase, patients should be seen on a monthly or bimonthly basis

#### Clinical examination

The clinical follow-up is identical to that carried out during the initial assessment, it should seek to clarify:

- if the disease is clinically controlled (mucosal, mucocutaneous or cutaneous lesions)
- If adverse effects related to treatment are present or absent
- Diabetes, high blood pressure, cardiac insufficiency (corticosteroids)
- Respiratory disorders, anaemia, hepatitis (dapsone, methotrexate)
- Infections, notably respiratory, hepatitis (corticosteroids, immunosuppressants)
- mental disorders (corticosteroids)
- myopathy, osteoporosis, avascular bone necrosis, glaucoma, cataract (glucocorticoids)
- haematological abnormalities (leucopenia), (immunosuppressants)

#### Serological monitoring of disease activity

Determination of serum autoantibodies at the initiation of treatment, after 3 months and every 3–6 months based on the evolution, or in case of relapse by:

- ELISA: anti-Dsg1 and/or Dsg3 IgG
- If ELISA is not available: IIF microscopy utilizing monkey oesophagus
- Overall, serum concentrations of IgG autoantibodies against Dsg1 and Dsg3 correlate with the clinical activity of pemphigus and may thus help in therapeutic decision making

#### Discontinuation of Treatment

- Discontinuation of treatment is primarily based on the clinical symptoms but may be also supported by the findings of Dsg ELISA and/or IIF. In some clinical departments, negative direct IF microscopy of a skin biopsy is a prerequisite of termination of treatment
- Discontinuation of systemic corticosteroids may be proposed in patients in complete remission on minimal therapy (prednisolone or equivalent at  $\leq 10$  mg/day). The adjuvants may be stopped 6–12 months after achieving complete remission on therapy

#### Possible sequelae

Pemphigus may cause permanent sequelae not only due to the involvement of skin, conjunctivae, oral, pharyngeal, laryngeal, oesophageal, anogenital and anal mucosa but also due to side-effects of treatment, justifying request for recognition or help from departmental disability centres

#### Information for patients

Patients and their families must be informed about the disease, its clinical course and prognosis, treatment, relapse signs, possible adverse events associated with treatment.

- Patients should be informed about the existence of patients' self-support groups
- The purpose of these associations is to promote knowledge about the disease, provide comfort and share the experience of patients regarding daily life, and to provide information dissemination. It may contribute to a better overall management of the disease by promoting cooperation between patients, patient associations and health professionals. Patients are also informed about referral centres
- Patients should be alerted to potential triggers such as drugs, operations, radiation and physical trauma
- There is insufficient evidence to give dietetic restrictions

#### List of pemphigus support groups

- International Pemphigus and Pemphigoid Foundation
- [www.pemphigus.org](http://www.pemphigus.org)
- Pemphigus-Pemphigoid-France
- [www.pemphigus.asso.fr](http://www.pemphigus.asso.fr)
- Pemphigus Vulgaris Network
- [www.pemphigus.org.uk](http://www.pemphigus.org.uk)
- Pemphigus und Pemphigoid Selbsthilfe e. V.
- [www.pemphigus-pemphigoid-selbsthilfe.de](http://www.pemphigus-pemphigoid-selbsthilfe.de)
- Pemphigus-Forum
- [www.pemphigus-forum.de](http://www.pemphigus-forum.de)
- Associazione Nazionale Pemfigo/Pemfigoide Italy
- [www.pemfigo.it](http://www.pemfigo.it)
- Netwerk Nederland Pemphigus en Pemfigoïd
- [www.pemphigus.nl](http://www.pemphigus.nl)

#### Acknowledgement

We are indebted to Imke Eichenauer for her major contribution in the preparation of the written form of the guideline.

#### References

- 1 Joly P, Litrowski N. Pemphigus group (vulgaris, vegetans, foliaceus, herpetiformis, brasiliensis). *Clin Dermatol* 2011; **29**: 432–436.
- 2 Kneisel A, Hertl M. Autoimmune bullous skin diseases. Part 1: clinical manifestations. *J Dtsch Dermatol Ges* 2011; **9**: 844–856; quiz 857.
- 3 Kneisel A, Hertl M. Autoimmune bullous skin diseases. Part 2: diagnosis and therapy. *J Dtsch Dermatol Ges* 2011; **9**: 927–947.
- 4 Amagai M, Klaus-Kovtun V, Stanley JR. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. *Cell* 1991; **67**: 869–877.
- 5 Anhalt GJ, Labib RS, Voorhees JJ, Beals TF, Diaz LA. Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. *N Engl J Med* 1982; **306**: 1189–1196.
- 6 Martin LK, Werth V, Villanueva E, Segall J, Murrell DF. Interventions for pemphigus vulgaris and pemphigus foliaceus. *Cochrane Database Syst Rev* 2009; Jan 21;(1): CD006263.

- 7 Martin LK, Werth VP, Villaneuva EV, Murrell DF. A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. *J Am Acad Dermatol* 2011; **64**: 903–908.
- 8 Mimouni D, Noursari CH, Cummins DL, Kouba DJ, David M, Anhalt GJ. Differences and similarities among expert opinions on the diagnosis and treatment of pemphigus vulgaris. *J Am Acad Dermatol* 2003; **49**: 1059–1062.
- 9 Joly P, Bernard P, Bedane C, Prost C, Ingen-Housz-Oro S. Pemphigus. Guidelines for the diagnosis and treatment. Centres de reference des maladies bulleuses auto-immunes. Societe Francaise de Dermatologie. *Ann Dermatol Venereol* 2011; **138**: 252–258.
- 10 Harman KE, Albert S, Black MM. Guidelines for the management of pemphigus vulgaris. *Br J Dermatol* 2003; **149**: 926–937.
- 11 Poot AM, Diercks GF, Kramer D et al. Laboratory diagnosis of paraneoplastic pemphigus. *Br J Dermatol* 2013; **169**: 1016–1024.
- 12 Thompson AJ, Newman WG, Elliott RA, Roberts SA, Tricker K, Payne K. The cost-effectiveness of a pharmacogenetic test: a trial-based evaluation of TPMT genotyping for azathioprine. *Value Health* 2014; **17**: 22–33.
- 13 Mentink LF, Mackenzie MW, Toth GG et al. Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris: PEMPULS trial. *Arch Dermatol* 2006; **142**: 570–576.
- 14 Toth GG, Westerlaken BO, Eilders M, Laseur M, Jonkman MF, Uges DR. Dexamethasone pharmacokinetics after high-dose oral therapy for pemphigus. *Ann Pharmacother* 2002; **36**: 1108–1109.
- 15 Chams-Davatchi C, Mortazavizadeh A, Daneshpazhooh M et al. Randomized double blind trial of prednisolone and azathioprine, vs. prednisolone and placebo, in the treatment of pemphigus vulgaris. *J Eur Acad Dermatol Venereol* 2013; **27**(10): 1285–1292.
- 16 Beissert S, Werfel T, Frieling U et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. *Arch Dermatol* 2006; **142**: 1447–1454.
- 17 Beissert S, Mimouni D, Kanwar AJ, Solomons N, Kalia V, Anhalt GJ. Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. *J Invest Dermatol* 2010; **130**: 2041–2048.
- 18 Ioannides D, Apalla Z, Lazaridou E, Rigopoulos D. Evaluation of mycophenolate mofetil as a steroid-sparing agent in pemphigus: a randomized, prospective study. *J Eur Acad Dermatol Venereol* 2012; **26**: 855–860.
- 19 Chams-Davatchi C, Esmaili N, Daneshpazhooh M et al. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. *J Am Acad Dermatol* 2007; **57**: 622–628.
- 20 Badalamenti SA, Kerdel FA. Azathioprine. In: Wolverton SE, ed. *Comprehensive Dermatologic Drug Therapy*. 2nd ed. London: Elsevier, 2007: 183–195.
- 21 Meggitt SJ, Anstey AV, Mohd Mustapa MF, Reynolds NJ, Wakelin S. British Association of Dermatologists' guidelines for the safe and effective prescribing of azathioprine 2011. *Br J Dermatol* 2011; **165**: 711–734.
- 22 Kasperkiewicz M, Shimanovich I, Meier M et al. Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine/mycophenolate mofetil: a pilot study of 23 patients. *Br J Dermatol* 2012; **166**: 154–160.
- 23 Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. *N Engl J Med* 2006; **355**: 1772–1779.
- 24 Joly P, Mouquet H, Roujeau JC et al. A single cycle of rituximab for the treatment of severe pemphigus. *N Engl J Med* 2007; **357**: 545–552.
- 25 Hertl M, Zillikens D, Borradori L et al. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. *J Dtsch Dermatol Ges* 2008; **6**: 366–373.
- 26 Amagai M, Ikeda S, Shimizu H et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. *J Am Acad Dermatol* 2009; **60**: 595–603.
- 27 Zillikens D, Derfler K, Eming R et al. Recommendations for the use of immunoadsorption in the treatment of autoimmune bullous diseases. *J Dtsch Dermatol Ges* 2007; **5**: 881–887.
- 28 Behzad M, Möbs C, Kneisel A et al. Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris. *Br J Dermatol* 2012; **166**: 844–852.
- 29 Pasricha JS, Khaitan BK, Raman RS, Chandra M. Dexamethasone-cyclophosphamide pulse therapy for pemphigus. *Int J Dermatol* 1995; **34**: 875–882.
- 30 Noursari CH, Brodsky R, Anhalt GJ. Evaluating the role of immunosuppressive high-dose cyclophosphamide therapy in pemphigus vulgaris. *J Am Acad Dermatol* 2003; **49**: 148–150.
- 31 Baum S, Greenberger S, Samuelov L et al. Methotrexate is an effective and safe adjuvant therapy for pemphigus vulgaris. *Eur J Dermatol* 2012; **22**: 83–87.
- 32 Werth VP, Fivenson D, Pandya AG et al. Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. *Arch Dermatol* 2008; **144**: 25–32.
- 33 Iraj F, Asilian A, Siadat AH. Pimecrolimus 1% cream in the treatment of cutaneous lesions of pemphigus vulgaris: a double-blind, placebo-controlled clinical trial. *J Drugs Dermatol* 2010; **9**: 684–686.
- 34 Cohen SN, Lim RP, Paul CJ, Abdullah A. Equal efficacy of topical tacrolimus and clobetasone butyrate in pemphigus foliaceus. *Int J Dermatol* 2006; **45**: 1379.
- 35 Grossmann JM, Gordon R, Ranganath VK et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. *Arthritis Care Res* 2010; **62**: 1515–1526.
- 36 Guslandi M. Steroid ulcers: any news? *World J Gastrointest Pharmacol Ther* 2013; **4**: 39–40.
- 37 Murrell DF, Dick S, Ahmed AR et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. *J Am Acad Dermatol* 2008; **58**: 1043–1046.
- 38 Horvath B, Huizinga J, Pas HH, Mulder AB, Jonkman MF. Low-dose rituximab is effective in pemphigus. *Br J Dermatol* 2011; **166**: 405–412.
- 39 Kanwar AJ, Vinay K, Sawatkar GU et al. Clinical and immunological outcomes of high and low dose rituximab treatments in pemphigus patients: a randomized comparative observer blinded study. *Br J Dermatol* 2014; **170**(6): 1341–1349.
- 40 Amber K, Hertl M. An assessment of treatment history and its association with clinical outcomes and relapse in 155 pemphigus patients with response to a single cycle of rituximab. *J Eur Acad Dermatol Venereol*. 2014; Sep 3. doi: 10.1111/jdv.12678. [Epub ahead of print].
- 41 Carbone J. Adverse reactions and pathogen safety of intravenous immunoglobulin. *Curr Drug Saf* 2007; **2**: 9–18.